Articles Tagged With: rifampin
-
Infectious Disease Alert Updates
Plague in the 21st Century; Vertebral Osteomyelitis from Staphylococcus aureus; Rifampin in Vertebral Osteomyelitis Is Useful
-
Rifampin and Prosthetic Joint Infections
In patients with prosthetic joint infection, no modifiable surgical or antibiotic factors were independently associated with success or failure. Factors not associated with outcomes include the extent of debridement, exchange of mobile parts, use of rifampin or of ciprofloxacin, and duration of intravenous or oral antibiotic administration.
-
Staphylococcal Prosthetic Valve Endocarditis: Drop the Rifampin? And the Gentamicin?
In a retrospective study, the investigators failed to find evidence of benefit of adjunctive rifampin therapy in patients with staphylococcal prosthetic valve endocarditis. -
Rifampin vs. Isoniazid for Latent Tuberculosis
A health system cost comparison showed that four months of rifampin was safer and less expensive than nine months of isoniazid in high-income countries, medium-income countries, and African countries.
-
Four Months of Rifampin Is Just as Effective, Safer, and Less Expensive than Nine Months of Isoniazid for Latent Tuberculosis
A health system cost comparison found that four months of rifampin was safer and less expensive than nine months of isoniazid in high-income countries, medium-income countries, and African countries.
-
Trimethoprim Sulfamethoxazole Plus Clindamycin for Treatment of Staphylococcus aureus Endocarditis
A before-and-after intervention study compared 170 patients treated with either oxacillin IV or vancomycin IV for six weeks (plus gentamicin IV given during the first five days) to 171 patients who were treated with TMP/SMZ IV plus clindamycin IV for the first week followed by TMP/SMZ PO (without clindamycin) to complete a six-week course. Mortality and hospital length of stay were significantly less in the TMP/SMZ-treated patients.
-
Oral Antibiotics Are Noninferior to Intravenous for Bone and Joint Infections
In a randomized, controlled trial of adult patients with bone or joint infections, researchers found oral antibiotic therapy was noninferior to intravenous therapy based on treatment failure at one year.
-
Latent Tuberculosis Treatment With Four Months of Rifampin Compared to Nine Months of Isoniazid
In an open-label trial, adults with latent tuberculosis infection were randomized to either four months of treatment with rifampin or nine months of treatment with isoniazid. The four-month rifampin regimen was non-inferior to nine months of isoniazid for prevention of active tuberculosis. It also was associated with a higher treatment completion rate and superior safety.
-
Does Adding Rifampin to Standard Therapy Improve Outcomes in Patients With Staphylococcus aureus Bacteremia?
The addition of rifampin to standard therapy failed to provide significant benefit to patients with bacteremia due to Staphylococcus aureus.